Literature DB >> 8945710

Serological response to Chlamydia pneumoniae in patients with sarcoidosis.

M Puolakkainen1, L A Campbell, C C Kuo, M Leinonen, C Grönhagen-Riska, P Saikku.   

Abstract

The antigen-specific serological response to Chlamydia pneumoniae was studied in 24 patients with sarcoidosis and compared to that seen in acute C. pneumoniae respiratory infection. By the micro-immunofluorescence test, five sarcoidosis patients had acute antibody, 15 had chronic antibody and four had no antibody against C. pneumoniae. By enzyme immunoassay, 20 sarcoidosis patients had antibody against ReLPS but that cross-reacts with chlamydial LPS. Immunoblot analysis of sera using purified C. pneumoniae elementary bodies showed that recognition of the 40 kDa C. pneumoniae major outer membrane protein was rare (20%). Reactivities with proteins with Mw of 42 K (70%), 60 K (65%), 98 K (55%) and 52 K (50%) were often noted. To study reactivity of chlamydial HSP 60 in sarcoidosis sera, sarkosyl-soluble (contains the 60 kDa HSP) and sarkosyl-insoluble (contains the 60 kDa structural protein) fractions of C. pneumoniae elementary bodies were prepared. The 60 kDa structural protein was recognized with equal frequency by sera from patients with sarcoidosis and acute respiratory infection, while the HSP 60 was more frequently recognized by sera with acute respiratory infection than sarcoidosis. Recombinant fusion proteins expressed from pGEX-2T containing overlapping DNA fragments of the C. pneumoniae 60 kDa HSP gene were purified. Different recognition patterns were identified for sera from sarcoidosis patients and from patients with acute C. pneumoniae respiratory infection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8945710     DOI: 10.1016/s0163-4453(96)92273-2

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  8 in total

1.  Isolation of Chlamydia pneumoniae clonal variants by a focus-forming assay.

Authors:  Jens Gieffers; Robert J Belland; William Whitmire; Scot Ouellette; Deborah Crane; Matthias Maass; Gerald I Byrne; Harlan D Caldwell
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

2.  Interactions of antisera to different Chlamydia and Chlamydophila species with the ribosomal protein RPS27a correlate with impaired protein synthesis in a human choroid plexus papilloma cell line.

Authors:  Abdullah Almamy; Christian Schwerk; Horst Schroten; Hiroshi Ishikawa; Abdul Rahman Asif; Bernhard Reuss
Journal:  Immunol Res       Date:  2017-12       Impact factor: 2.829

3.  Evaluation of Chlamydia pneumoniae 43- and 53-kilodalton recombinant proteins for serodiagnosis by Western Blot.

Authors:  L A Campbell; S Roberts; S Inoue; L Kong; C C Kuo Cc
Journal:  Clin Diagn Lab Immunol       Date:  2001-11

4.  Chlamydia pneumoniae replicates in Kupffer cells in mouse model of liver infection.

Authors:  Antonella Marangoni; Manuela Donati; Francesca Cavrini; Rita Aldini; Silvia Accardo; Vittorio Sambri; Marco Montagnani; Roberto Cevenini
Journal:  World J Gastroenterol       Date:  2006-10-28       Impact factor: 5.742

5.  Is C. Pneumoniae research in peril?

Authors:  Katerina Wolf
Journal:  Front Microbiol       Date:  2011-03-21       Impact factor: 5.640

Review 6.  Is there any association between Sarcoidosis and infectious agents?: a systematic review and meta-analysis.

Authors:  Tiago Esteves; Gloria Aparicio; Vicente Garcia-Patos
Journal:  BMC Pulm Med       Date:  2016-11-28       Impact factor: 3.317

7.  High throughput 16SrRNA gene sequencing reveals the correlation between Propionibacterium acnes and sarcoidosis.

Authors:  Meng-Meng Zhao; Shan-Shan Du; Qiu-Hong Li; Tao Chen; Hui Qiu; Qin Wu; Shan-Shan Chen; Ying Zhou; Yuan Zhang; Yang Hu; Yi-Liang Su; Li Shen; Fen Zhang; Dong Weng; Hui-Ping Li
Journal:  Respir Res       Date:  2017-02-01

8.  Detection of parvovirus B19 and Chlamydophila pneumoniae in a patient with atypical sarcoidosis.

Authors:  C Contini; D Segala; R Cultrera; V M Crapanzano Minichello
Journal:  Infection       Date:  2007-09-28       Impact factor: 7.455

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.